ChemicalBook CAS DataBase List MRTX-1719

MRTX-1719

Product NameMRTX-1719
CAS2630904-45-7
CBNumberCB29782000
MFC23H18ClFN6O2
MW464.89
MOL File2630904-45-7.mol
MSDS FileSDS

Chemical Properties

Density	1.58±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	Acetonitrile: Soluble DMSO: Soluble
pka	11.37±0.40(Predicted)
form	Solid
color	White to light yellow
InChIKey	BZKIOORWZAXIBA-UHFFFAOYSA-N
SMILES	CN1N=CC(C2=CC=C3C(NN=C(CN)C3=C2)=O)=C1C1C(=C(Cl)C=C(OC2CC2)C=1C#N)F

MRTX-1719 Price

Product number	Packaging	Price	Product description	Buy
Cayman Chemical 36563	1mg	$191	MRTX-1719 ≥95%	Buy
Cayman Chemical 36563	5mg	$905	MRTX-1719 ≥95%	Buy
Cayman Chemical 36563	10mg	$1142	MRTX-1719 ≥95%	Buy
ChemScene CS-0226219	1mg	$227	Navlimetostat 99.16%	Buy
ChemScene CS-0226219	5mg	$932	Navlimetostat 99.16%	Buy

MRTX-1719 Chemical Properties,Usage,Production

Uses

Navlimetostat is a potent, orally active, selective PRMT5MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5MTA and PRMT5. Navlimetostat binds to the PRMT5MTA complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study[1][2].

Biological Activity

MRTX-1719 is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAPDEL SDMA cells[1].

in vivo

Navlimetostat (12.5-100 mg/kg/d for p.o., 21 day) reduces the tumor growth in Lu-99 orthotopic xenograft tumor models^[2].

Pharmacokinetic Analysis ^[2]

Model	Route	Dose (mg/kg)	Cl_total (mL/min/kg)	V_dss (L/kg)	t_1/2 (h)
CD-1 mouse.	i.v.	3	83	6.3	1.5
Beagle dog	i.v.	2	14	3.4	4.8
Cynomolgus monkey	i.v.	2	15	2.3	6.1

Model	Route	Dose (mg/kg)	C_max (ug/mL)	AUC_inf (h*ug/mL)	F (%)
CD-1 mouse.	p.o.	30	1.16	4.85	80
Beagle dog	p.o.	10	1.40	7.47	59
Cynomolgus monkey	p.o.	10	/	/	41

Animal Model:	Lu-99 (an MTAP/CDKN2A-deleted human lung cancer cell line ) xenograft tumor models^[2]
Dosage:	12.5, 25, 50, and 100 mg/kg/d, 21 day
Administration:	Oral gavage
Result:	Reduced the tumor volume with 86% tumor growth inhibition (TGI) at 50 mg/kg and 88% TGI at 100 mg/kg.

IC 50

PRMT5

References

[1] Targeting the genetic and immunological drivers of cancer.
[2] CHRISTOPHER R. SMITH*. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers[J]. Journal of Medicinal Chemistry, 2022, 65 3: 1749-1766. DOI: 10.1021/acs.jmedchem.1c01900

Preparation Products And Raw materials

MRTX-1719 Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	20122	58
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32466	58
BOC Sciences	16314854226; +16314854226	inquiry@bocsci.com	United States	19853	58
Nantong HI-FUTURE Biology Co., Ltd.	+undefined18051384581	sales@chemhifuture.com	China	3135	58
TargetMol Chemicals Inc.	+1-781-999-5354;	support@targetmol.com	United States	39040	58
Chemtour Biotech Co., Ltd	+8617327281506	market@chemtour.com	China	1521	58
SHANGHAI KEAN TECHNOLOGY CO., LTD.	+8613817748580	cooperation@kean-chem.com	China	40066	58
Chengdu DingDang Pharmaceutical Co., Ltd.	028-86040038 13980902949;	market@dingdangchem.com	China	1854	55
Suzhou Meidi Senuo Pharmaceutical Technology Co., Ltd.	13771642864	snhuyu_2008@126.com	China	1189	58

View Lastest Price from MRTX-1719 manufacturers

MRTX-1719 Spectrum

2630904-45-7, MRTX-1719Related Search

Send Inquriy